Filing Flows › Keros Therapeutics (KROS) › Q1 2026 › vs Q4 2025
Keros Therapeutics (KROS) Q1 2026 vs Q4 2025 (quarter over quarter)
Keros Therapeutics's revenue fell $13K (-3%) from $380K in Q4 2025 to $367K in Q1 2026.
Keros Therapeutics, Q1 2026: revenue $367K (-100% year over year), net loss $23.7M, operating cash flow −$3.5M. The chart draws each line against Q4 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q4 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $367K | $380K | −$13K | -3% |
| Other income, net | $2.2M | $4.3M | −$2.1M | -49% |
| Net loss | $23.7M | $23.5M | $247K | +1% |
| Costs & expenses | $26.2M | $29.6M | −$3.4M | -11% |
| Operating costs | $26.2M | $29.6M | −$3.4M | -11% |
| Research & development | $16.1M | $17.9M | −$1.8M | -10% |
| General & admin | $10.1M | $11.7M | −$1.6M | -14% |
| Operating cash sources | $23.7M | $23.5M | $247K | +1% |
| Depreciation | $403K | $400K | $3K | +0.8% |
| Share-based compensation | $6.2M | $7.3M | −$1.1M | -15% |
| Working capital & other | $13.6M | −$11.5M | $25.1M | — |
| Cash used in operations | $3.5M | $27.3M | −$23.8M | -87% |
| Net loss absorbed | $23.7M | $23.5M | $247K | +1% |
Questions
How much did Keros Therapeutics's revenue grow quarter over quarter in Q1 2026?
Keros Therapeutics's revenue fell $13K (-3%) from $380K in Q4 2025 to $367K in Q1 2026.